호르몬 대체요법과 안 질환: 제4기 국민건강영양조사자료

임형택 ( Hyung Taek Rim ),박선영 ( Sun Young Park ),윤진숙 ( Jin Sook Yoon ) 한국안전학회(구 한국산업안전학회) 2003 International Journal of Safety Vol.2 No.1

목적: 호르몬대체요법과 안질환의 관계를 밝히고자 하였다. 대상과 방법: 5,808명의 제4기 국민건강영양조사를 완료한 여성중 호르몬 대체요법 시행 군과 받지 않은 군 간의 안질환 유병을 회귀분석을 통한 보정 평균을 비교하였다. 결과: 호르몬 대체요법을 시행 받은 군의 수는 480명(8.3%)이었고, 근시는 호르몬대체요법을 시행 군에서 44.5% (95%CI, 38.1-51.2), 시행 받지 않은 군에서 54.4% (95%CI, 52.6-56.1)이며, 원시는 시행 군에서 7.7% (95%CI, 5.5-10.6), 시행 받지 않은 군에서 4.5%(95%CI, 3.8-5.3)이며, 익상편은 시행 군에서 2.1% (95%CI, 1.3-3.3), 시행 받지 않은 군에서 3.3% (95%CI, 2.7-4.0)로 p-value 0.05 미만의 통계적 유의한 차이를 보였고, 당뇨망막증은 시행 군에서 5.6% (95%CI, 1.4-19.8), 시행 받지 않은 군에서 16.7% (95%CI, 13.0-21.2)로 p-value 0.053으로 통계적으로 의미 있는 경계에 놓여 있었다. 결론: 호르몬대체요법 시행 군에서 근시, 익상편과 당뇨망막증은 적었고, 원시는 많았다. Purpose: To identify the association between hormone replacement therapy and eye diseases. Methods: The fourth Korea National Health and Nutrition Examination Survey (KNHANES IV) is a nationwide survey. The study included 5,808 females who completed the KNHANES IV. The prevalence of eye disease of adjusted mean using linear regression analysis between the subjects who had hormone replacement therapy and those who did not have the therapy was analyzed. Results: Among the 5,808 females, 480 (8.3%) received hormone replacement therapy. The adjusted prevalence of myopia was 44.5% (95% CI, 38.1-51.2) in the subjects who received hormone replacement therapy, and 54.4% (95% CI, 52.6-56.1) in those who did not have the therapy. The adjusted prevalence of hyperopia was 7.7% (95% CI, 5.5-10.6) in subjects who received hormone replacement therapy and 4.5% (95% CI, 3.8-5.3) in those who did not have the therapy. The adjusted prevalence of pterygium was 2.1% (95% CI, 1.3-3.3) in the subjects who received hormone replacement therapy and 3.3% (95% CI, 2.7-4.0) in those who did not have the therapy. All the results were statistically significant with a p-value <0.05. The adjusted prevalence of diabetic retinopathy was 5.6% (95% CI, 1.4-19.8) in the subjects who received hormone replacement therapy and 16.7% (95% CI, 13.0-21.2) in those who did have the therapy. The p-value was 0.053, which is marginally statistically significant. Conclusions: The adjusted prevalence of myopia, pterygium, and diabetic retinopathy in the subjects who received hormone replacement therapy was low, although hyperopia was statistically significantly high. J Korean Ophthalmol Soc 2012;53(10):1445-1450

호르몬 대체요법과 안 질환: 제4기 국민건강영양조사자료

임형택,박선영,윤진숙,Hyung Taek Rim,MD,Sun Young Park,MD,Jin Sook Yoon,MD 대한안과학회 2012 대한안과학회지 Vol.53 No.10

Purpose: To identify the association between hormone replacement therapy and eye diseases. Methods: The fourth Korea National Health and Nutrition Examination Survey (KNHANES IV) is a nationwide survey. The study included 5,808 females who completed the KNHANES IV. The prevalence of eye disease of adjusted mean using linear regression analysis between the subjects who had hormone replacement therapy and those who did not have the therapy was analyzed. Results: Among the 5,808 females, 480 (8.3%) received hormone replacement therapy. The adjusted prevalence of myopia was 44.5% (95% CI, 38.1-51.2) in the subjects who received hormone replacement therapy, and 54.4% (95% CI, 52.6-56.1) in those who did not have the therapy. The adjusted prevalence of hyperopia was 7.7% (95% CI, 5.5-10.6) in subjects who received hormone replacement therapy and 4.5% (95% CI, 3.8-5.3) in those who did not have the therapy. The adjusted prevalence of pterygium was 2.1% (95% CI, 1.3-3.3) in the subjects who received hormone replacement therapy and 3.3% (95% CI, 2.7-4.0) in those who did not have the therapy. All the results were statistically significant with a p-value <0.05. The adjusted prevalence of diabetic retinopathy was 5.6% (95% CI, 1.4-19.8) in the subjects who received hormone replacement therapy and 16.7% (95% CI, 13.0-21.2) in those who did have the therapy. The p-value was 0.053, which is marginally statistically significant. Conclusions: The adjusted prevalence of myopia, pterygium, and diabetic retinopathy in the subjects who received hormone replacement therapy was low, although hyperopia was statistically significantly high. J Korean Ophthalmol Soc 2012;53(10):1445-1450

갱년기 여성의 호르몬 대치 요법에 대한 수용율

이임순,장진영,이정재,이순곤,이권해,이해혁,김승형 순천향의학연구소 1997 Journal of Soonchunhyang Medical Science Vol.3 No.2

Purpose: We have evaluated the compliance of hormone replacement therapy. Method: There are 185 climacteric women who are divided into three groups (Group I, Group II, Group III). Group I is given conjugated equine estrogen(CEE, 0.625mg, day 1-30) plus medroxyprogesterone acetate(MPA, 5mg, day 1-12). Group II is given conjugated equine estrogen (CEE, 0.625mg, day 1-30) plus medroxyprogesterone acetate (MPA, 2.5mg, day 1-30), Group III is given only conjugated equine estrogen(CEE, 0.625mg, day 1-30). Results: 1) The compliance rate of hormone replacement therapy during three months is 77.9% including each Group I : 77.7%, Group Ⅱ : 76.1%, Group Ⅲ :80.4%. 2) The compliance rate of hormone replacement therapy during six months is 60.7% including each Group Ⅰ:52.9%, Group Ⅱ: 56.4%, Group Ⅲ: 79.5%. 3) The compliance rate of hormone replacement therapy during nine months is 49.7% including each Group Ⅰ: 45.5%, Group Ⅱ:41.7%, Group Ⅲ: 64.3%. 4) The compliance rate of hormone replacement therapy during a year is 44.4% including each Group Ⅰ: 40.2%, Group Ⅱ:35.3%, Group Ⅲ: 59.5%. Conclusion : It is vital that we maximize compliance if patients are to receive the full benefits from hormone replacement therapy. We think that physicians who prescribe hormone replacement therapy for climacteric women should enough explain the purpose, risks, and side effect of treatment for maximizing compliance of hormone replacement therapy.

호르몬 치료를 받던 폐경 후 여성에서 발생한 악성 혼합 뮐러종양 1예

황인철,김경곤,이기범,이경식,서희선,국명진,나서영 대한가정의학회 2009 Korean Journal of Family Medicine Vol.30 No.9

Hormone therapy for peri- and postmenopausal women is widely used for relieving vasomotor symptoms or preventing osteoporosis. Even though exogenous hormone is the most common cause of vaginal bleeding in postmenopausal women under hormone therapy, in clinical practice, physicians must never exclude the possibility of endometrial disorders, such as endometrial hyperplasia or cancer. Taking thorough medical history and performing physical and pelvic examinations are essential for the evaluation of abnormal uterine bleeding in menopausal hormone therapy. Transvaginal ultrasonography, endometrial aspiration biopsy, dilatation and curettage, and hysteroscopy are the options which physicians may use. This case is about a woman with continuous combined hormone therapy for 5 years who had experienced rather sudden onset of vaginal spotting lasting for several months and was fi nally diagnosed as having malignant mixed Müllerian tumor. Our purpose is to inquire into the proper approaching steps for vaginal bleeding in menopausal hormone therapy 갱년기 및 폐경기 여성 호르몬 치료는 폐경기 증상의 완화와 골다공증의 예방을 목적으로 광범위하게 사용되고 있다. 호 르몬 요법을 받고 있는 폐경기 여성에서 질 출혈의 가장 흔한 원인은 외인성 호르몬이기는 하지만, 실제 환자 진료 시에는 자궁내막증식증이나 자궁내막암과 같은 자궁내막질환의 가 능성에 대해서도 항상 염두에 두어야 한다. 갱년기 호르몬 치 료에서 나타나는 비정상 자궁 출혈을 평가하기 위해서는 자 세한 병력 청취, 신체 검진 및 골반 검진은 필수사항이며, 이 외 질경유 초음파 검사, 자궁내막 흡인생검, 경관확장 자궁소파 술, 그리고 자궁경 검사 등의 검사법을 통해 도움을 받을 수 있 다. 본 증례는 5년간 지속적 복합호르몬 요법을 받아오던 환자 가 갑작스러운 소량의 파탄성 출혈을 주소로 내원하여, 최적 의 평가 및 검사를 통해 악성혼합 뮐러종양을 진단받은 경우 이다. 저자들은 본 고를 통해 호르몬 치료를 받던 환자에게 비 정상 자궁출혈이 발생하였을 때 고려해야 할 사항들과 그에 따른 적절한 접근 방법 및 단계별 검사의 의미에 대해 고찰함 으로써 일차진료에서의 호르몬 치료에 도움이 되고자 한다.

The Survey on Korean Menopausal Women`s Behavior and Perception of Hormone Therapy

( Nam Kung Jeong ),( Youn Jee Chung ),( Jae Eun Ha ),( Hyun Hee Jo ),( Eun Jung Kim ),( Dong Jin Kwon ),( Young Ok Lew ),( Jang Heub Kim ),( Mee Ran Kim ) 대한폐경학회 2011 대한폐경학회지 Vol.17 No.3

연구목적: 폐경 여성에서 호르몬 요법은 그 이점이 많음에도 불구하고 WHI 연구 결과 발표 이후로 호르몬 요법에 대한 인식의 전환으로 호르몬 사용이 감소되었다. 이에 본 연구는 폐경 증상으로 병원을 방문한 여성 중 폐경 여성의 호르몬 요법에 대한 반응과 인지도 및 태도에 대해 조사하였다. 연구재료 및 방법: 본 연구는 2009년 9월부터 2009년 10월까지 4주간에 걸쳐 폐경 증상으로 병원을 방문한 45~64세 여성으로 대상으로 하여 설문을 통해 조사하였다. 설문은 일대일 직접 면담을 통해 30분 이내로 이뤄졌으며 대상군을 45~49세, 50~54세, 55~59세, 60~64세로 구분하여 각각 150명씩 총 600명의 여성을 대상으로 하였다. 결과: 폐경 증상으로 찾은 병원의 형태는 산부인과가 80%를 차지하였다. 그 중 현재까지 호르몬을 복용하고 있는 여성은 16%, 그 외 84%는 호르몬 치료 경험이 전혀 없거나 (53%) 사용하다가 중단한 경우였다 (31%). 호르몬 사용자중에서 단지 9%만이 5년 이상 호르몬 요법을 받았고 80%에서는 호르몬 사용기간이 2년 이내로 나타났다. 호르몬 요법경험 여부와 관계없이 가장 불편한 증상은 안면 홍조였으며, 의사가 권유했을 때 72%의 환자에서 호르몬 요법을 받아들였다. 호르몬 비사용자의 경우 호르몬 요법을 받지 않은 가장 큰 이유가 부작용 때문이었으며 (51%), 그 중에서도 암에 대한 우려가 67%로 나타났다. 결론: 폐경 증상 호전에 있어 호르몬 요법이 효과적임에도 불구하고 많은 여성에서 호르몬 요법을 받아들이지 않고, 호르몬 요법을 시작했더라도 반수 이상에서 호르몬 요법을 중단한다. 가장 흔한 이유는 부작용에 대한 걱정, 그중에서도 암 발생과 관련된 우려 때문인 것으로 나타났다. 따라서 폐경기 호르몬 요법은 폐경 증상 호전과 삶의 질향상을 위해 가능한 단기간 최소 용량으로 사용하는 것이 좋겠다. Objectives: After Women`s Health Initiative (WHI) study had been published, the use of hormone therapy (HT) have been decreasing even though it is the most effective therapy for menopausal symptom. The survey was conducted to investigate Korean menopausal women`s perception of HT and behavior when they are treated by HT. Methods: During 4 weeks from September 2009 to October 2009, total 600 women aged 45~64 participated in the survey by face to face interview. Out of answering women, women who have visited clinic/hospital at least 1 time to treat their menopausal symptom during last 1 year were included. One hundred fifty women for each age group, 45~49, 50~54, 55~59 and 60~64, were recruited in consecutive order. Results: Eighty percent women who have visited clinic/hospital to treat menopausal symptom, visited obstetrics and gynecology. Only 16% of these women were current user, and other 84% of these women had no experience of HT (53%) or stopped therapy (31%). Among current user, only 9% of women have used HT more than 5 years. Eighty percent of current user had used HT less than 2 years. Most distressing menopausal symptom is ``hot flush`` regardless HT experience. When doctor recommend HT, 72% of patients accept HT in overall. Among women who had no experience of HT, the most common reason of not to take HT was concern of side effects (51%). And 67% of women who had concern of side effects worried about cancer incidence. Conclusion: Many women with menopausal symptom do not take HT even though it is the most effective therapy. Most of women who take HT stop treatment within 1 year. Most common reason of not to take HT is concern about side effect, increasing incidence of cancer related to HT. Therefore, HT should be considered to short-term relief of menopausal symptoms and at the minimal dose, if possible. (J Korean Soc Menopause 2011;17:142-149)

Awareness and Experience of Menopausal Symptom and Hormone Therapy in Korean Postmenopausal Women

( Hee Dong Chae ),( Sun Young Choi ),( Eun Ji Cho ),( Yoo Mi Cho ),( Sa Ra Lee ),( Eun Sil Lee ),( Hyoung Moo Park ) 대한폐경학회 2014 대한폐경학회지 Vol.20 No.1

Objectives: To investigate awareness and experience of menopausal symptom and hormone therapy in Korean postmenopausal women. Methods: A total of 570 postmenopausal women were accepted our survey. The women filled out the questionnaires composed of medical and surgical history, menopausal age and symptom, demand of treatment on menopausal symptom, and personal method for overcoming the symptom. Also, we make inquiries about experience of hormone therapy, concern about hormone therapy, improvement of menopausal symptom after therapy, adverse effect, and cause of cease the therapy. Results: According to the survey, 80% (456/570) of the women experienced menopausal symptom. When they felt the symptom at first, 47% (213/570) of women was 46-50 years old. The most common menopausal symptom was hot flushes (141/570). A number of Korean women regarded that menopause was a natural process of ageing (69%). Eighty two % of women thought to need to have treatment on menopausal symptom. However, only half (43%) visited doctor. The most concerned disease after menopause they had answered was osteoporosis (60%) but only 22% of women were taken regular check-up of bone mineral density. The common causes were unwilling to do treatment were concern about adverse effect (51%) and indefinite fear of cancer (32%). Moreover, many women got diverse information about menopause from the mass media than professional advice. Conclusion: Only a minority of Korean postmenopausal women with menopausal symptoms had taken a hormone therapy. We should provide appropriate education and counsel to Korean peri-menopause women.

Recurrence-Free Survival after Postoperative Hormone Therapy for Catamenial Pneumothorax

Kim Ji Hoon,Woo Won-Gi,Jung Yong-Ho,Moon Duk Hwan,Lee Sungsoo 대한심장혈관흉부외과학회 2024 Journal of Chest Surgery (J Chest Surg) Vol.57 No.5

Background: Catamenial pneumothorax (CP) is a rare form of spontaneous pneumothorax that is linked to endometriosis; thus, it predominantly manifests in women of reproductive age. Considerable research has explored the potential benefits of postoperative hormone therapy following various surgical interventions. This study was performed to examine the clinical implications of postoperative hormone treatment in patients with CP. Methods: The study included patients who underwent surgical intervention for CP between November 2009 and February 2023. These procedures included wedge resection, diaphragm resection, and total pleural coverage. Recurrence-free survival was analyzed using the Kaplan-Meier log-rank test to assess the impact of hormone therapy. Additionally, Cox proportional hazards analysis was employed to identify risk factors associated with postoperative CP recurrence. Results: The study included 41 patients, with a median age of 38.4 years. Among them, 27 individuals received hormone therapy, 8 of whom experienced recurrence during a median follow-up period of 1 year. Patients who received hormone therapy exhibited a lower rate of recurrence than those who did not; however, the difference was not statistically significant, likely due to the small sample size. Side effects of hormone therapy included depression (6.8%), excessive sweating (3.4%), and headache (3.4%). In the analysis of risk factors for postoperative recurrence, diaphragm resection emerged as a protective factor (hazard ratio, 0.16; 95% confidence interval, 0.03–0.77; p=0.022). Conclusion: Hormone treatment combined with surgery did not significantly impact recurrence in patients with CP. The application of diaphragm resection was the sole factor that displayed significance in preventing CP recurrence.

폐경기 증후군 환자의 호르몬 대체요법에 따른 자각증상의 호전에 관한 연구

김희숙,정혁 조선의대 1996 The Medical Journal of Chosun University Vol.21 No.2

지지적 미술치료가 진폐증환자의 불안, 우울, 삶의 질, 스트레스 호르몬 및 면역기능에 미치는 영향

장애화 한국임상치유예술학회 2015 임상예술치료연구 Vol.4 No.1

The purpose of this study was to investigate the quality of life, biological parameters such as stress hormones and immune function and psychopathological parameters such as depression and anxiety of the patients with pneumoconiosis, and the effect of supportive art therapy on the these variables. Ten patients with pneumoconiosis participated in supportive art therapy from April, 2007 to October, 2007. Each patients self-assessed level of anxiety, depression and quality of life at baseline and a following supportive art therapy. Subjects used Spielberger state-trait anxiety inventory(STAI) for measuring anxiety and Beck depression inventory(BDI) for measuring depression. Quality of life was assessed by short-form 36 health survey-Korean(SF-36-K). Lab tests of norepinephrine, epinephrine, Ig G, Ig M, Ig A, natural killer cell and cortisol were performed before and after supportive group art therapy; 1. After supportive group art therapy, the level of depression was significantly decreased.(50.89 ± .33 vs 34. 66 ± 3. 50, p<.01) 2. After supportive group art therapy, the level of state and trait anxiety were significantly decreased.(state anxiety 80.00 ± .00. vs 46.55 ± 2. 78 p<.01, trait anxiety 71.00 ± .00 vs 68.66 ± 2.73, p<.05) 3. The quality of life was significantly increased after supportive group art therapy. (46.20 ±.00 vs 68. 87 ± 2. 58, p<.01) 4. After the supportive art therapy, the norepinephrine, IgG, IgA, IgM, and cortisol of the pneumoconiosis patients significantly increased. But their epinephrine and T suppressor cells significantly decreased. 5. Only social support among state-1, state-2, depression, social support, and health, which were the psychological factors of the pneumoconiosis patients, was related to some factors for blood. There was positive correlation between social support and epinephrine, and negative correlation between social support and NK cells. The prevalence of anxiety and depression were high and the quality of life was low in patients with pneumoconiosis patients. Group supportive art therapy significantly affects the anxiety, depression, quality of life, and immune function of pneumoconiosis patients and helps improve their physical and metal health. Thus, since supportive art therapy helps chronic pneumoconiosis patients improve their physical, mental, social, and psychological health, it can be used as a adjunctive method for treatment. 지지적 미술치료가 진폐증 환자의 불안, 우울, 사회적 지지, 건강과 관련된 삶의 질과 스트레스 호르몬 및 면역기능에 미치는 영향을 알아보고자 하였다. 2007년 4월에서 10월 까지 10명의 진폐증 환자가 지지적 정신치료에 참여하였다. 각각의 환자들에 대해 지지적 미술치료 전 ․ 후에 불안, 우울, 그리고 삶의 질에 대한 자가 평가를 시행하였다. 불안에 대한 평가를 위해 Spielberger state-trait anxiety inventory (STAI)가 사용되었고 우울에 대한 평가를 위해 Beck depression inventory (BDI)가 사용되었다. 삶의 질에 대한 접근을 위해 36 health survey-Korean(SF-36-K)이 사용되었다. 지지적 미술치료 치료 전 ․ 후에 혈중 norepinephrine, epinephrine, Ig G, Ig M, Ig A, natural killer cell과 cortisol에 대한 혈중 농도 검사가 시행되었다. 첫째, 지지적 집단 미술치료 후, 우울의 수준은 유의하게 감소되었다. (50.89 ± .33 vs 34. 66 ± 3. 50, p<.01) 둘째, 지지적 집단 미술치료 후, 불안의 수준은 유의하게 감소되었다. (state anxiety 80.00 ± .00. vs 46.55 ± 2. 78 p<.01, trait anxiety 71.00 ± .00 vs 68.66 ± 2.73, p<.05) 셋째, 지지적 집단 미술치료 후, 삶의 질은 유의하게 개선되었다. (46.20 ±.00 vs 68. 87 ± 2. 58, p<.01) 넷째, 지지적 집단 미술치료 후, 진폐증 환자의 혈중 norepinephrine, IgG, IgA, IgM, 그리고 cortisol 수치가 저명하게 증가하였다. 그러나 epinephrine과 T suppressor cells은 유의하게 감소되었다. 다섯째, 진폐증 환자에 있어서 정신의학적 요소 즉, state 1과 state 2사이의 사회적 지지와 우울, 사회적 지지, 그리고 건강은 혈액의 몇 가지 요소와 관계가 있다. 사회적 지지와 epinephrine 사이에는 정 상관관계가 있었으며 사회적 지지와 NK cells사이에는 역 상관관계가 있었다. 결론: 진폐증 환자에서 불안과 우울증의 유병율이 높았으며 삶의 질은 저하되어 있었다. 미술치료를 받은 집단에서 불안, 우울, 삶의 질, 그리고 면역 기능의 저명한 개선이 있었으며, 또한 육체적, 정신적 건강에 도움이 되었다. 따라서 지지적 미술치료는 만성 진폐증 환자의 육체적, 정신적, 사회적 그리고 심리학적 건강에 도움이 되므로 보조적 치료법으로 활용할 수 있을 것으로 판단된다.

한국 여성에서 호르몬 치료 중 진단된 유방암의 임상적 특성

이동윤,윤병구,김미란,정혜원,이병석,강병문,최훈,박형무,김정구 대한폐경학회 2009 대한폐경학회지 Vol.15 No.3

연구목적: 한국 여성에서 호르몬 치료 중 발견된 유방암의 임상적 특성을 조사하였다. 연구재료 및 방법: 호르몬 치료 중 유방암을 진단받은 95명의 여성을 대상으로 임상적 특성, 호르몬 치료 및 유방암에 대한 정보를 차트 리뷰를 통해 후향적으로 분석하였다. 결과: 평균 초경 연령은 15.6±1.6세이었고, 폐경 연령과 암 진단 연령은 각각 48.0±5.0 및 54.1±6.3세이었다. 에스트로겐 단독 요법을 받은 여성은 38%, 에스트로겐-프로게스토겐 병합 요법을 받은 여성이 57%이었다. 호르몬 치료를 받은 기간은 평균 41.3개월이었고, 36.8% (35/95)는 호르몬 치료를 시작한 후 2년 이내에 유방암이 발견되었다. 40%(38/95)는 유방암 위험인자를 동반하고 있었다. 93% (88/95)에서 일차 치료로서 수술이 시행되었으며, 유방 보존 수술의 비율은 38.6% (34/88)였다. 94% (85/90)의 환자에서 관암종이 진단되었다. 76% (62/82)는 좋은 예후를 시사하는 인자를 동반하였는데, 0기 및 1기의 비율은 63.3% (50/79), 종양 크기가 2 cm 미만인 경우가 66.2% (49/74), 에스트로겐 수용체양성인 경우가 65.3% (47/72), 그리고 액와부 임파선 침범이 없는 경우가 74.0% (57/77)이었다. 결론: 한국 여성에서 호르몬 치료 중 발견된 유방암은 대부분 초기에 진단되며 악성도가 낮아 좋은 예후를 기대할 수 있을 것으로 생각된다. Objectives: This study was performed to evaluate clinical characteristics of breast cancers diagnosed in Korean women on hormone therapy (HT). Methods: In 95 patients who were diagnosed with primary breast cancer under current HT, information on clinical characteristics, HT, and breast cancer was derived from the medical records. Results: The mean age of menarche, menopause, and cancer diagnosis (±SD) was 15.6±1.6, 48.0±5.0, and 54.1±6.3 years, respectively. Thirty-eight percent of the patients received estrogen therapy and the 62% of the patients received combination therapy. The duration of HT was 41.3±34.9 months (range, 1∼151 months). Of note, 36.8% of the patients (35/95) received HT for <2 years. Forty percent of the patients (38/95) of patients had risk factor(s) for breast cancer. Ninety-three percent of the patients (88/95) underwent surgery as a primary treatment, and breast conservation surgery was performed in 38.6% of the patients (34/88). Ductal cancer was the histologic diagnosis in 94.4% of the patients (85/90). Seventy-six percent of the patients (62/82) had at least 1 of the following good prognostic factors: stages 0 and I, 63.3% (50/79) tumor size <2 cm, 66.2% (49/74) estrogen receptor-positive tumors, 65.3% (47/72) and tumors without axillary lymph node involvement, 74.0% (57/77). Conclusion: This retrospective study suggests that breast cancer diagnosed in Korean women while taking HT have a favorable prognosis, possibly due to earlier detection and lower biologic aggressiveness. (J Korean Soc Menopause 2009;15:172-177)